Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sascha Rutz

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Journal of Experimental Medicine|July 30, 2008
Autoregulation of Th1-mediated inflammation by twist1Uwe Niesner, Inka Albrecht, Marko Janke, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization and <i>In Vivo</i> Characterization of a Series of Cbl‑b Inactive-State InhibitorsMichael J Lambrecht, Jun Liang, Peter Man-Un Ung, et al.
ACS Medicinal Chemistry Letters|June 19, 2024
Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate BindingJun Liang, Michael J Lambrecht, Teresita L Arenzana, et al.
Science Advances|May 6, 2026
Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunityJunghyun Lim, Katherine Williams, Stephanie Mittman, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated <i>In Vivo</i> EfficacyJun Liang, Michael J Lambrecht, Malcolm P Huestis, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Journal of Experimental Medicine|July 30, 2008
Autoregulation of Th1-mediated inflammation by twist1Uwe Niesner, Inka Albrecht, Marko Janke, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization and <i>In Vivo</i> Characterization of a Series of Cbl‑b Inactive-State InhibitorsMichael J Lambrecht, Jun Liang, Peter Man-Un Ung, et al.
ACS Medicinal Chemistry Letters|June 19, 2024
Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate BindingJun Liang, Michael J Lambrecht, Teresita L Arenzana, et al.
Science Advances|May 6, 2026
Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunityJunghyun Lim, Katherine Williams, Stephanie Mittman, et al.
ACS Medicinal Chemistry Letters|June 17, 2026
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated <i>In Vivo</i> EfficacyJun Liang, Michael J Lambrecht, Malcolm P Huestis, et al.
Pageof 5